Eperisone hydrochloride and Diclofenac sodium + Eperisone hydrochloride
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Musculoskeletal Spasm Due to Low Back Pain
Conditions
Acute Musculoskeletal Spasm Due to Low Back Pain
Trial Timeline
Feb 1, 2011 → Sep 1, 2011
NCT ID
NCT01300312About Eperisone hydrochloride and Diclofenac sodium + Eperisone hydrochloride
Eperisone hydrochloride and Diclofenac sodium + Eperisone hydrochloride is a phase 3 stage product being developed by Eisai for Acute Musculoskeletal Spasm Due to Low Back Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT01300312. Target conditions include Acute Musculoskeletal Spasm Due to Low Back Pain.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01300312 | Phase 3 | Completed |
Competing Products
20 competing products in Acute Musculoskeletal Spasm Due to Low Back Pain